Global Procurement Strategist — Negotiation
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
Pensaert & Partners BV in Gent zoekt een ervaren Procurement Specialist die strategische inkoop ontzorgt en kosten, kwaliteit en continuïteit optimaliseert. Je neemt onderhandelingen zelfstandig op met leveranciers en stuurt initiatieven aan.
Je analyseert markten, legt prijstrends bloot en werkt nauw samen met interne stakeholders om tijdige en voordelige inkoopmomenten te bepalen en duurzame relaties op te bouwen.
-
Head of Global Supply Chain, Procurement
Il y a 24 heures
Gent, Gent, Belgique Legend Biotech US Temps plein 238 000 € - 316 000 € ContratHead of Global Supply Chain, Procurement & Sourcing Legend Biotech is a global biotechnology company dedicated to treating and, one day, curing life-threatening diseases. Headquartered in Bridgewater, New Jersey, we are advancing the next generation of cell therapy through a portfolio of innovative technologies, including autologous, allogeneic, and in vivo...
-
Head of Specialized Sourcing
Il y a 21 heures
Gent, Belgique argenx Temps plein 152 000 € - 209 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Head of Specialized Sourcing
Il y a 4 semaines
Gent, Belgium, 00 Argen X Temps plein 152 000 € - 209 000 € Contrat*Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...